KLRS – kalaris therapeutics, inc. (US:NASDAQ)

News

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Kalaris Therapeutics (NASDAQ:KLRS) was given a new $19.00 price target on by analysts at Chardan Capital.
Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by analysts at Wall Stre
Kalaris Therapeutics (NASDAQ:KLRS) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com